CClinicalTrials.gg
RecruitingNCT06467708tAN-TBIUpdated Sep 30, 2026

Transcutaneous Auricular Neurostimulation for ICU Patients With Traumatic Brain Injury

An interventional study of Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) in TBI (Traumatic Brain Injury), sponsored by University of Texas Southwestern Medical Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The overarching goal of this pilot study is to assess the feasibility and safety of transcutaneous auricular neurostimulation (tan) in ICU patients with TBi and to determine the effect of tan on serum markers of inflammation. exploratory analyses will examine effects on such physiological parameters as blood pressure, heart rate, and intracranial pressure (iCP), as well as measures of neurological function.

Read the detailed description

This is a single-center, open-label, nonrandomized investigation. TBI patients with a post resuscitation Glasgow Coma Scale (GCS) score of 12 or less (commonly described as moderate or severe TBI) and acute traumatic intradural blood on head CT scan will be screened upon admission to the ICU at Parkland Memorial Hospital. It is expected that all or almost all subjects will be in the Neuroscience or Surgical ICU. Consent for participation will be sought from the subject's legally authorized representative. Exception from informed consent or waiver of consent will not be part of this study.

tAN will begin as soon as feasible after subject enrollment. Immediately prior to this intervention, vital signs, neurologic status, and other clinical parameters will be recorded, and pre-tAN blood will be collected for measurement of serum inflammatory markers. tAN will be administered for 30 minutes under the supervision of a member of the research team. After 30 minutes (just prior to stopping tAN), the same clinical parameters that were recorded at baseline will again be recorded then tAN will be stopped. Approximately two hours after tAN has ended, a post-tAN blood sample will be collected for measurement of the same inflammatory markers as in the pre-tAN blood sample. At each timepoint for blood collection, additional blood may be collected for banking and future analyses.

Patients will undergo research blood draws and tAN stimulation for a maximum of 10 days. Research-related procedures will not exceed this 10-day period.

02

Conditions studied

  • TBI (Traumatic Brain Injury)

Keywords

  • Transcutaneous auricular neurostimulation (tAN)
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Post-resuscitation GCS score 12 or below and acute trauma-related intradural blood on head CT scan after TB
  2. Age 18 years or older (pediatric trauma patients are not routinely transported to Parkland)
  3. Consent from legally authorized representative

Exclusion criteria

Exclusion Criteria:

  1. Hemodynamic instability
  2. Expected imminent mortality because of overwhelming neurological and/or systemic injury
  3. Unclear neurological status because of paralytic medications or intoxication with ethanol or other drugs
  4. Presence of other electrical stimulation devices (pacemaker, cochlear prosthesis, neurostimulator, etc.)
  5. Abnormal ear anatomy or ear infection
  6. Participant is pregnant or lactating
  7. Any other significant medical or psychosocial problems that, in the opinion of the investigator, would potentially cause harm to the participant, impact their ability to participate, or influence the results of the trial
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Determine the effect of tAN on serum concentrations of inflammatory mediators in TBI patients

    Subjects will receive treatment upon providing informed consent and will undergo transcutaneous auricular neurostimulation (tAN) once daily during their ICU stay, with the treatment duration not exceeding 10 days. Two blood samples will be collected daily: one before the tAN session and another two hours after the session. Participant data will be collected daily throughout the ICU stay. Additionally, surveys will be collected from registered nurses providing direct care to TBI patients enrolled in the tAN-TBI study to assess the compatibility of tAN with patient care processes in the ICU.

    Device: Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)

Interventions

  • DeviceSparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)

    This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS).

05

What researchers measure

Primary outcomes

  1. Survey nursing attitudes towards daily tAN and the compatibility of tAN with standard patient care activities in the ICU; Examine the safety of tAN in ICU patients.

    Registered nurses providing direct care to ICU patients receiving tAN will be asked to complete the Sparrow Ascent ICU User Acceptance Questionnaire to assess the compatibility of tAN with patient care.

    Time frame: Registered nurses can complete the Sparrow Ascent ICU User Acceptance Questionnaire at Day 1- Day 10, or before the TBI patient is discharged from the hospital, or ICU. It may not be completed on Day 11 or after the patient has been discharged.

  2. Determine the effect of tAN on serum concentrations of inflammatory mediators in TBI patients.

    Every effort will be made to initiate tAN as soon after injury as possible in order to capture early postinjury data on the effectiveness of tAN and to inform the design of future studies.

    Time frame: TBI patients will receive tAN stimulation once per day and will not exceed 10 days.

  3. Explore the effect of tAN on Blood Pressure

    Blood pressure (mmHg) will be checked twice daily, pre-tAN and 30 minutes post-tAN

    Time frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.

  4. Explore the effect of tAN on Heart Rate

    Heart rate (bpm) will be checked twice daily, pre-tAN and 30 minutes post-tAN

    Time frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.

  5. Explore the effect of tAN on Respiratory Rate (and ventilator settings and use of noninvasive oxygenation and ventilation if applicable)

    Respiratory rate (bpm) will be checked twice daily, pre-tAN and 30 minutes post-tAN

    Time frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.

  6. Explore the effect of tAN on Temperature

    Temperature (°C/°F) will be checked twice daily, pre-tAN and 30 minutes post-tAN

    Time frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.

  7. Explore the effect of tAN on Intracranial pressure

    Intracranial pressure (mmHg) will be checked twice daily, pre-tAN and 30 minutes post-tAN

    Time frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.

  8. Explore the effect of tAN on Brain Tissue Oxygen Tension (PbtO2)

    Brain Tissue Oxygen Tension (mmHg) will be checked twice daily, pre-tAN and 30 minutes post-tAN

    Time frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.

  9. Explore the effect of tAN on Glasgow Coma Scale (GCS) (and any sedatives or analgesics that could affect neurological assessment)

    GCS (and any sedatives or analgesics that could affect neurological assessment) will be checked twice daily, pre-tAN and 30 minutes post-tAN. Scale from 3 to 15, where 3 represents deep unconsciousness and 15 indicates full consciousness.

    Time frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.

  10. Explore the effect of tAN on Pupillary Diameter

    Pupillary Diameter (mm) will be checked twice daily, pre-tAN and 30 minutes post-tAN

    Time frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.

  11. Explore the effect of tAN on Neurological Pupil index (NPi) via pupillometry

    Neurological Pupil index (NPi) via pupillometry dimensionless index, typically ranging from 0 to 5. This will be checked twice daily, pre-tAN and 30 minutes post-tAN

    Time frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.

06

Study locations

2 of 2 sites recruiting
07

Registry details

Key details

Study ID
NCT06467708
Lead sponsor
University of Texas Southwestern Medical Center
Responsible party
Alex Valadka (Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jun 21, 2024
Start date
Feb 11, 2025
Primary completion
Feb 11, 2027 (estimated)
Completion
Feb 11, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Alex Valadka, MD
Contact
alex.valadka@utsouthwestern.edu
2146452300
Aisha Qureshi
Contact
Aisha.Qureshi@UTSouthwestern.edu
2146489905
Alex Valadka, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion